Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are male and have been diagnosed with prostate cancer that has spread to other parts of the body, and whose cancer still responds to hormone treatment (known as metastatic hormone-sensitive prostate cancer)
- People who have been dispensed at least one of the following medications for the first time during the study period, specifically for this type of prostate cancer: darolutamide, enzalutamide, apalutamide, or abiraterone acetate/methylprednisolone
- People who were 18 years of age or older at the time their records entered the study
- People whose medical records include at least 12 months of data before the point they entered the study
- People whose medical records include at least 3 months of data after the point they entered the study
Who may not be able to join:
- People who have records showing use of any of the listed medications (darolutamide, enzalutamide, apalutamide, or abiraterone/methylprednisolone) before the point they entered the study
- People whose records show evidence of prostate cancer that has stopped responding to hormone treatment (castration-resistant prostate cancer), whether or not it has spread, at or before the point they entered the study (confirm with trial site on how this is determined from medication records)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (+)1-888-84 22937
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number and proportion of patients taking each ARPI as a percentage of total study population.; Demographic characteristics of mHSPC patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.